Literature DB >> 29526026

CXCL5 regulation of proliferation and migration in human non-small cell lung cancer cells.

Lin Wang1, Lin Shi2, Jie Gu1, Cheng Zhan1, Junjie Xi3, Jianyong Ding4, Di Ge1.   

Abstract

Epithelial neutrophil-activating peptide-78 (CXCL5), a member of the subgroup of CXC-type chemokine family, is an inflammatory factor involved in the progression of lung cancer, but the underlying mechanism remains unclear. In this study, we investigated the effects of CXCL5 on proliferation and migration in non-small cell lung cancer (NSCLC) using tissue microarrays from NSCLC patients and H460 cells transfected with a CXCL5-interfered lentivirus vector or stimulated with recombinant CXCL5. We observed that the expression of CXCL5 was significantly higher in lung cancer cell lines, and high CXCL5 was associated with high chemokine (C-X-C motif) receptor 2 expression and was significantly associated with poor differentiation. The high expression of CXCL5 was associated with poor NSCLC prognosis and was an independent predictive factor. Furthermore, downregulation of CXCL5 in H460 cells significantly reduced proliferation and migration. Recombinant CXCL5 promoted H460 cell proliferation and movement by activating MAPK/ERK1/2 and PI3K/AKT signaling. Our study elucidates the important role of CXCL5 in the progression and prognosis of NSCLC. These findings suggested that CXCL5 might be a potential biomarker and novel therapeutic target for lung cancer.

Entities:  

Keywords:  CXCL5; Lung cancer; MAPK/ERK1/2; Migration; PI3K/AKT; Proliferation

Mesh:

Substances:

Year:  2018        PMID: 29526026     DOI: 10.1007/s13105-018-0619-z

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  34 in total

1.  Chemokine receptor CXCR4 expression and lung cancer prognosis: a meta-analysis.

Authors:  Jin-Xiao Liang; Wei Gao; Yong Liang; Xin-Ming Zhou
Journal:  Int J Clin Exp Med       Date:  2015-04-15

2.  Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.

Authors:  Simona Coco; Anna Truini; Angela Alama; Maria Giovanna Dal Bello; Roberta Venè; Anna Garuti; Enrico Carminati; Erika Rijavec; Carlo Genova; Giulia Barletta; Claudio Sini; Alberto Ballestrero; Francesco Boccardo; Francesco Grossi
Journal:  Target Oncol       Date:  2014-10-25       Impact factor: 4.493

3.  CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.

Authors:  Shao-Lai Zhou; Zheng-Jun Zhou; Zhi-Qiang Hu; Xun Li; Xiao-Wu Huang; Zheng Wang; Jia Fan; Zhi Dai; Jian Zhou
Journal:  Cancer Lett       Date:  2014-11-24       Impact factor: 8.679

4.  Cyclic AMP signaling reduces sirtuin 6 expression in non-small cell lung cancer cells by promoting ubiquitin-proteasomal degradation via inhibition of the Raf-MEK-ERK (Raf/mitogen-activated extracellular signal-regulated kinase/extracellular signal-regulated kinase) pathway.

Authors:  Eui-Jun Kim; Yong-Sung Juhnn
Journal:  J Biol Chem       Date:  2015-02-24       Impact factor: 5.157

5.  Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma.

Authors:  Jane Yanagawa; Tonya C Walser; Li X Zhu; Longsheng Hong; Michael C Fishbein; Vei Mah; David Chia; Lee Goodglick; David A Elashoff; Jie Luo; Clara E Magyar; Mariam Dohadwala; Jay M Lee; Maie A St John; Robert M Strieter; Sherven Sharma; Steven M Dubinett
Journal:  Clin Cancer Res       Date:  2009-11-03       Impact factor: 12.531

6.  Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases.

Authors:  Vilma Oliveira Frick; Claudia Rubie; Mathias Wagner; Stefan Graeber; Henner Grimm; Berit Kopp; Bettina M Rau; Martin K Schilling
Journal:  Pancreatology       Date:  2008-09-03       Impact factor: 3.996

7.  CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment.

Authors:  Artjoms Spaks; Darja Svirina; Irina Spaka; Inta Jaunalksne; Donats Breiva; Ilmars Tracums; Dainis Krievins
Journal:  Biomarkers       Date:  2016-04-21       Impact factor: 2.658

8.  Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer.

Authors:  D A Arenberg; M P Keane; B DiGiovine; S L Kunkel; S B Morris; Y Y Xue; M D Burdick; M C Glass; M D Iannettoni; R M Strieter
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

9.  Circulating inflammation markers and prospective risk for lung cancer.

Authors:  Meredith S Shiels; Ruth M Pfeiffer; Allan Hildesheim; Eric A Engels; Troy J Kemp; Ju-Hyun Park; Hormuzd A Katki; Jill Koshiol; Gloriana Shelton; Neil E Caporaso; Ligia A Pinto; Anil K Chaturvedi
Journal:  J Natl Cancer Inst       Date:  2013-11-18       Impact factor: 13.506

Review 10.  Dual role of inflammatory mediators in cancer.

Authors:  T G Shrihari
Journal:  Ecancermedicalscience       Date:  2017-02-23
View more
  14 in total

Review 1.  Chemokine signaling in cancer-stroma communications.

Authors:  Arun J Singh; Joe W Gray
Journal:  J Cell Commun Signal       Date:  2021-06-04       Impact factor: 5.782

2.  Identification of the dominant angiogenic CXCL class chemokines associated with non-small cell lung cancer via bioinformatics tools.

Authors:  Nese Unver
Journal:  Med Oncol       Date:  2021-05-13       Impact factor: 3.064

3.  Epigenetic alterations of CXCL5 in Cr(VI)-induced carcinogenesis.

Authors:  Xin Ge; Jun He; Lin Wang; Lei Zhao; Yifang Wang; Gang Wu; Wenjing Liu; Yongqian Shu; Wei Gong; Xin-Liang Ma; Yajing Wang; Bing-Hua Jiang; Ling-Zhi Liu
Journal:  Sci Total Environ       Date:  2022-06-01       Impact factor: 10.753

Review 4.  Role of chemokine systems in cancer and inflammatory diseases.

Authors:  Hongyi Li; Min Wu; Xia Zhao
Journal:  MedComm (2020)       Date:  2022-06-08

5.  Establishment and characterization of a patient-derived circulating lung tumor cell line in vitro and in vivo.

Authors:  Zujun Que; Bin Luo; Zhiyi Zhou; Changsheng Dong; Yi Jiang; Lin Wang; Qihui Shi; Jianhui Tian
Journal:  Cancer Cell Int       Date:  2019-01-29       Impact factor: 5.722

6.  CXCL5 Modified Nanoparticle Surface Improves CXCR2+ Cell Selective Internalization.

Authors:  Roberta Cagliani; Francesca Gatto; Giulia Cibecchini; Roberto Marotta; Federico Catalano; Paola Sanchez-Moreno; Pier Paolo Pompa; Giuseppe Bardi
Journal:  Cells       Date:  2019-12-24       Impact factor: 6.600

7.  Identification of an Immune Gene Expression Signature for Predicting Lung Squamous Cell Carcinoma Prognosis.

Authors:  Yubo Yan; Minghui Zhang; Shanqi Xu; Shidong Xu
Journal:  Biomed Res Int       Date:  2020-06-27       Impact factor: 3.411

8.  (-)-Oleocanthal as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer.

Authors:  Abu Bakar Siddique; Phillip C S R Kilgore; Afsana Tajmim; Sitanshu S Singh; Sharon A Meyer; Seetharama D Jois; Urska Cvek; Marjan Trutschl; Khalid A El Sayed
Journal:  Nutrients       Date:  2020-06-11       Impact factor: 5.717

Review 9.  CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target.

Authors:  Wen Zhang; Huishan Wang; Mingyang Sun; Xueting Deng; Xueru Wu; Yilan Ma; Mengjing Li; Said Maisam Shuoa; Qiang You; Lin Miao
Journal:  Cancer Commun (Lond)       Date:  2020-03

Review 10.  Role of Cytokines and Chemokines in NSCLC Immune Navigation and Proliferation.

Authors:  Sowmya Ramachandran; Amit K Verma; Kapil Dev; Yamini Goyal; Deepti Bhatt; Mohammed A Alsahli; Arshad Husain Rahmani; Ahmad Almatroudi; Saleh A Almatroodi; Faris Alrumaihi; Naushad Ahmad Khan
Journal:  Oxid Med Cell Longev       Date:  2021-07-16       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.